AbstractBackgroundMutations in the progranulin (PGRN) encoding gene, GRN, cause familial frontotemporal dementia (FTD) and neuronal ceroid lipofuscinosis and is also implicated in Parkinson’s disease. These mutations result in decreased PGRN expression. PGRN is highly expressed in peripheral immune cells and microglia and regulates cell growth, survival, repair, and inflammation. As well, PGRN is implicated in regulating lysosome function, however, the exact role of PGRN in lysosomal function and how this contributes to inflammation and degeneration is not entirely understood. To better understand the role of PGRN in regulating lysosome function, I examined how loss of GRN impacts lysosomal and cathepsin activity.MethodUsing mouse embryonic fibroblasts (MEFs), I performed immunocytochemistry and immunoblotting assays to analyze fluorescent signal from LAMP1 (lysosomal marker) and BMV109 (marker for cathepsin activity).ResultGRN‐/‐ MEFs exhibit increased expression of pan‐cathepsin activity relative to GRN+/+ MEFs, and significantly impacts expression of LAMP1.ConclusionThe significant increase in pan‐cathepsin activity in the GRN‐/‐ MEFs confirms that PGRN loss does alter cathepsin expression, which may be a result of compensatory mechanisms happening within the cell. Further investigations will include assessing LAMP1 and BMV109 expression in microglia from from GRN‐/‐ mice, in the hopes to understand the role of PGRN in lysosomal function in immune cells of the central nervous system and the diseases in which it is implicated.